Income Statement Cuorips Inc.

Stocks

4894

JP3266030000

Pharmaceuticals

Delayed Japan Exchange 20:45:30 2026-09-28 EDT			5-day change	1st Jan Change
5,600.00 ^JPY	-2.27%		-5.09%	-7.30%

09-11	Cuorips Inc. announced that it expects to receive ¥2.9999677 billion in funding from JIC Venture Growth Investments Co., Ltd.	CI
02-19	Japan Panel Clears First iPS Cell Therapies for Conditional Sale	MT

33da298a7a13be56f76d56.9cPXHFLUK2ROeKq02LDI1VMRvm4yVau7anhTG_xVV-g.vpygLSG_WSwpLebet-ahvD4i-QhHDPTqIg9iS5gRBtqd8pxqGZZZVCYVyQ

Published financial data: CUORIPS INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: March	2024 (JPY)	2025 (JPY)	2026 (JPY)
Revenues	23M	175M	212M
Total Revenues	23M	175M	212M
Cost of Goods Sold, Total	13M	7M	82M
Gross Profit	10M	168M	130M
Selling General & Admin Expenses, Total	388M	423M	576M
R&D Expenses	209M	334M	634M
Depreciation & Amortization - (IS)	1M	1M	1M
Other Operating Expenses, Total	598M	758M	1.21B
Operating Income	-588M	-590M	-1.08B
Interest And Investment Income	-	4M	13M
Net Interest Expenses	-	4M	13M
Currency Exchange Gains (Loss)	-	-36M	13M
Other Non Operating Income (Expenses)	-41M	-18M	4M
EBT, Excl. Unusual Items	-629M	-640M	-1.05B
Gain (Loss) On Sale Of Investments	1M	-1M	24M
Asset Writedown	-3M	-	-
Other Unusual Items	1M	-	1M
EBT, Incl. Unusual Items	-630M	-641M	-1.03B
Income Tax Expense	2M	3M	3M
Earnings From Continuing Operations	-632M	-644M	-1.03B
Net Income to Company	-632M	-644M	-1.03B
Minority Interest	-	-	7M
Net Income - (IS)	-632M	-644M	-1.02B
Net Income to Common Incl Extra Items	-632M	-644M	-1.02B
Net Income to Common Excl. Extra Items	-632M	-644M	-1.02B
Per Share Items
Net EPS - Basic	-85.84	-80.48	-124.47
Basic EPS - Continuing Operations	-85.84	-80.48	-124.47
Basic Weighted Average Shares Outstanding	7.36M	8M	8.21M
Net EPS - Diluted	-85.84	-80.48	-124.47
Diluted EPS - Continuing Operations	-85.84	-80.48	-124.47
Diluted Weighted Average Shares Outstanding	7.36M	8M	8.21M
Normalized Basic EPS	-53.4	-49.99	-79.15
Normalized Diluted EPS	-53.4	-49.99	-79.15
Supplemental Items
EBITDA	-518M	-514M	-997M
EBITA	-588M	-590M	-1.08B
EBIT	-588M	-590M	-1.08B
Effective Tax Rate - (Ratio)	-0.32	-0.47	-0.29
Normalized Net Income	-393M	-400M	-650M
Supplemental Operating Expense Items
General and Administrative Expenses	76M	111M	175M
Research And Development Expense From Footnotes	209M	334M	634M

Fiscal Period: March	2024 (JPY)	2025 (JPY)	2026 (JPY)
Assets
Cash And Equivalents	5.56B	4.59B	3.65B
Short Term Investments	21M	199M	246M
Total Cash And Short Term Investments	5.58B	4.79B	3.9B
Accounts Receivable, Total	-	6M	-
Total Receivables	-	6M	-
Inventory	1M	45M	64M
Other Current Assets, Total	29M	281M	457M
Total Current Assets	5.61B	5.12B	4.42B
Net Property Plant And Equipment	514M	514M	502M
Long-term Investments	41M	71M	71M
Other Intangibles, Total	17M	30M	128M
Other Long-Term Assets, Total	-	1M	2M
Total Assets	6.18B	5.74B	5.12B
Liabilities
Accounts Payable, Total	-	-	4M
Current Income Taxes Payable	137M	156M	263M
Other Current Liabilities	29M	21M	10M
Total Current Liabilities	166M	177M	277M
Deferred Tax Liability Non Current	6M	6M	5M
Other Non Current Liabilities	30M	30M	73M
Total Liabilities	202M	213M	355M
Common Stock, Total	1.59B	1.67B	1.77B
Additional Paid In Capital	6.49B	6.56B	6.67B
Retained Earnings	-2.1B	-2.75B	-3.77B
Treasury Stock	-12M	-12M	-12M
Comprehensive Income and Other	8M	52M	89M
Total Common Equity	5.98B	5.53B	4.75B
Minority Interest	1M	2M	18M
Total Equity	5.98B	5.53B	4.77B
Total Liabilities And Equity	6.18B	5.74B	5.12B
Supplemental Items
ECS Total Shares Outstanding on Filing Date	7.95M	8.1M	8.26M
ECS Total Common Shares Outstanding	7.95M	8.09M	8.26M
Book Value / Share	752.1	682.79	575.24
Tangible Book Value	5.96B	5.5B	4.62B
Tangible Book Value Per Share	749.97	679.08	559.73
Total Debt	0	0	0
Net Debt	-5.58B	-4.79B	-3.9B
Minority Interest, Total (Incl. Fin. Div)	1M	2M	18M
Inventories - Raw Materials, Total	-	11M	25M
Inventories - Work In Process, Total	1M	29M	36M
Inventories - Finished Goods, Total	-	3M	3M
Inventories - Others	-	2M	-
Full Time Employees	59	56	51

Fiscal Period: March	2024 (JPY)	2025 (JPY)	2026 (JPY)
Net Income	-629M	-642M	-1.03B
Depreciation & Amortization - CF	70M	76M	84M
Depreciation & Amortization, Total	70M	76M	84M
(Gain) Loss From Sale Of Asset	3M	-	-
(Gain) Loss on Sale of Investments - (CF)	-1M	1M	-24M
Other Operating Activities, Total	-1M	3M	5M
Change In Accounts Receivable	2M	-160M	157M
Change In Inventories	3M	-44M	-19M
Change In Accounts Payable	77M	19M	-32M
Change in Other Net Operating Assets	25M	-65M	-204M
Cash from Operations	-451M	-812M	-1.06B
Capital Expenditure	-23M	-80M	-43M
Sale (Purchase) of Intangible assets	-12M	-9M	-6M
Other Investing Activities, Total	1M	-30M	15M
Cash from Investing	-34M	-119M	-34M
Issuance of Common Stock	3.14B	145M	177M
Other Financing Activities, Total	-17M	0	27M
Cash from Financing	3.12B	145M	204M
Foreign Exchange Rate Adjustments	1M	-	-3M
Miscellaneous Cash Flow Adjustments	-1M	-2M	-1M
Net Change in Cash	2.64B	-788M	-893M
Supplemental Items
Cash Income Tax Paid (Refund)	2M	5M	2M
Levered Free Cash Flow	-	-673M	-730M
Unlevered Free Cash Flow	-	-673M	-730M
Change In Net Working Capital	-	291M	89M

Fiscal Period: March	2024 (JPY)	2025 (JPY)	2026 (JPY)
Profitability
Return on Assets	-	-6.18	-12.44
Return on Total Capital	-	-6.41	-13.12
Return On Equity %	-	-11.19	-19.99
Return on Common Equity	-	-11.19	-19.89
Margin Analysis
Gross Profit Margin %	43.48	96	61.32
SG&A Margin	1.69K	241.71	271.7
EBITDA Margin %	-2.25K	-293.71	-470.28
EBITA Margin %	-2.56K	-337.14	-509.91
EBIT Margin %	-2.56K	-337.14	-509.91
Income From Continuing Operations Margin %	-2.75K	-368	-485.38
Net Income Margin %	-2.75K	-368	-482.08
Net Avail. For Common Margin %	-2.75K	-368	-482.08
Normalized Net Income Margin	-1.71K	-228.57	-306.54
Levered Free Cash Flow Margin	-	-384.43	-344.16
Unlevered Free Cash Flow Margin	-	-384.43	-344.16
Asset Turnover
Asset Turnover	-	0.03	0.04
Fixed Assets Turnover	-	0.34	0.42
Inventory Turnover (Average Inventory)	-	0.3	1.5
Short Term Liquidity
Current Ratio	33.81	28.95	15.96
Quick Ratio	33.63	27.11	14.08
Operating Cash Flow to Current Liabilities	-2.72	-4.59	-3.82
Days Outstanding Inventory (Average Inventory)	-	1.2K	242.59
Long Term Solvency
Total Liabilities / Total Assets	3.27	3.71	6.93
Net Debt / EBITDA	10.78	9.32	3.91
Net Debt / (EBITDA - Capex)	10.32	8.07	3.75
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	-	660.87	21.14
Gross Profit, 1 Yr. Growth %	-	1.58K	-22.62
EBITDA, 1 Yr. Growth %	-	-0.77	93.97
EBITA, 1 Yr. Growth %	-	0.34	83.22
EBIT, 1 Yr. Growth %	-	0.34	83.22
Earnings From Cont. Operations, 1 Yr. Growth %	-	1.9	59.78
Net Income, 1 Yr. Growth %	-	1.9	58.7
Normalized Net Income, 1 Yr. Growth %	-	1.75	62.47
Diluted EPS Before Extra, 1 Yr. Growth %	-	-6.25	54.66
Inventory, 1 Yr. Growth %	-	4.4K	42.22
Net Property, Plant and Equip., 1 Yr. Growth %	-	0	-2.33
Total Assets, 1 Yr. Growth %	-	-7.16	-10.76
Tangible Book Value, 1 Yr. Growth %	-	-7.85	-15.9
Common Equity, 1 Yr. Growth %	-	-7.61	-14.04
Cash From Operations, 1 Yr. Growth %	-	80.04	30.42
Capital Expenditures, 1 Yr. Growth %	-	247.83	-46.25
Levered Free Cash Flow, 1 Yr. Growth %	-	-	8.45
Unlevered Free Cash Flow, 1 Yr. Growth %	-	-	8.45
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	-	-	203.6
Gross Profit, 2 Yr. CAGR %	-	-	260.56
EBITDA, 2 Yr. CAGR %	-	-	38.73
EBITA, 2 Yr. CAGR %	-	-	35.59
EBIT, 2 Yr. CAGR %	-	-	35.59
Earnings From Cont. Operations, 2 Yr. CAGR %	-	-	27.6
Net Income, 2 Yr. CAGR %	-	-	27.16
Normalized Net Income, 2 Yr. CAGR %	-	-	28.57
Diluted EPS Before Extra, 2 Yr. CAGR %	-	-	20.41
Inventory, 2 Yr. CAGR %	-	-	700
Net Property, Plant and Equip., 2 Yr. CAGR %	-	-	-1.17
Total Assets, 2 Yr. CAGR %	-	-	-8.98
Tangible Book Value, 2 Yr. CAGR %	-	-	-11.97
Common Equity, 2 Yr. CAGR %	-	-	-10.88
Cash From Operations, 2 Yr. CAGR %	-	-	53.24
Capital Expenditures, 2 Yr. CAGR %	-	-	36.73